Iptacopan Alternatives Compared
| Iptacopan | Ultomiris (ravulizumab) | Empaveli (pegcetacoplan) |
|
|---|
| Iptacopan | Ultomiris (ravulizumab) | Empaveli (pegcetacoplan) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for C3 Glomerulopathy, Immunoglobulin A Nephropathy, Paroxysmal Nocturnal Hemoglobinuria. Iptacopan may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Myasthenia Gravis, Neuromyelitis Optica Spectrum Disorder, Hemolytic Uremic Syndrome, Paroxysmal Nocturnal Hemoglobinuria. Ultomiris may also be used for purposes not listed in this... View more |
Prescription only
Prescribed for Paroxysmal Nocturnal Hemoglobinuria. Empaveli may also be used for purposes not listed in this medication guide. |
Related suggestions Paroxysmal Nocturnal Hemoglobinuria
|
|||||||
| More about Iptacopan | More about Ultomiris (ravulizumab) | More about Empaveli (pegcetacoplan) | ||||||||
| Ratings & Reviews | ||||||||||
|
Be the first to share your experience with this drug. |
Ultomiris has an average rating of 9.5 out of 10 from a total of 8 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Be the first to share your experience with this drug. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||
|
View all Iptacopan side effects |
View all Ultomiris side effects |
View all Empaveli side effects |
||||||||
| Drug Class | ||||||||||
| Generic Availability | ||||||||||
|
N/A |
N/A |
|||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Ultomiris prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | ||||||||||
|
N/A |
|
N/A |
||||||||
| Brand Names | ||||||||||
| Fabhalta |
N/A |
N/A |
||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||
|
25 hours |
1192.8 hours |
192 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 339 drugs are known to interact with Iptacopan:
|
A total of 89 drugs are known to interact with Ultomiris:
|
A total of 82 drugs are known to interact with Empaveli:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | ||||||||||
| First Approval Date | ||||||||||
|
December 05, 2023 |
December 21, 2018 |
N/A |
||||||||
| WADA Class View classifications | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| More Information | ||||||||||
| Patient Resources | ||||||||||
| Professional Resources | ||||||||||
| Related Treatment Guide | ||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.